What is valenTx?
Headquartered in Maple Grove, Minnesota, valenTx Inc. operates at the forefront of medical device engineering. The company specializes in the development of innovative, non-surgical, implantable solutions designed to provide effective, long-term management for patients suffering from morbid obesity and type-II diabetes. By focusing on less invasive alternatives to traditional bariatric surgery, valenTx aims to reduce procedural risks while improving patient outcomes and quality of life. Its market position is defined by a commitment to rigorous clinical validation and the pursuit of breakthrough technologies that address large, underserved patient populations within the metabolic health landscape.
How much funding has valenTx raised?
valenTx has raised a total of $25.2M across 3 funding rounds:
Series A
$772K
Series B
$20.3M
Debt
$4.1M
Series A (2004): $772K, investors not publicly disclosed
Series B (2009): $20.3M led by SV Health Investors, Sapient Capital Management, Affinity Capital Management, Covidien Ventures, Kaiser Permanente Ventures, and EDF Ventures
Debt (2014): $4.1M supported by EDF Ventures and SV Life Sciences
Key Investors in valenTx
SV Health Investors
SV Health Investors is a specialist investment firm backing innovative health care and life science companies, partnering with founders and management to provide capital, sector expertise and active support from early growth through scale and value creation.
EDF Ventures
EDF Ventures is a leading venture capital firm investing in early-stage healthcare companies, focusing on breakthrough technologies that address large, well-recognized problems or transform existing markets.
Kaiser Permanente Ventures
Kaiser Permanente Ventures is a national leader in strategic venture investing in healthcare, focusing on advancing innovation and bridging the gap between the healthcare system and the innovation ecosystem.
What's next for valenTx?
Looking ahead, valenTx is poised to leverage its recent capital infusion to accelerate clinical trials and navigate the complex regulatory pathways required for commercialization. The strategic focus remains on scaling manufacturing capabilities and expanding the clinical evidence base to support broader adoption of its implantable devices. As the company transitions from development to potential market entry, the ongoing support from its seasoned investor base will be critical in navigating the competitive healthcare environment. Future milestones will likely center on achieving key regulatory clearances and establishing partnerships with healthcare delivery systems to integrate these novel therapies into standard clinical practice, ultimately aiming to provide a scalable solution for the chronic disease epidemic.
See full valenTx company page
